ArticleEClinicalMedicine2025

Safety and feasibility of anlotinib in children with high risk, recurrent or refractory sarcomas: an open-label, single-centre, single-arm, phase Ia/Ib trial.

Suying Lu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.